OncoHost

📍 Binyamina, Israel🗓 Founded 2017👥 51 employees💰 Last funded May 2022
Hospitals and Health Care🌐 oncohost.com
Website LinkedIn
OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. OncoHost’s proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphet® NSCLC test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.
3
Total investors
0
Early stage
3
Mid stage
0
Late stage
2017
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Israel
3
Investor activity2021–2022 · investors recorded per year
2021220221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in OncoHost?
OncoHost has 3 investors on record on gritt.io, 3 mid-stage.
When did OncoHost last raise funding?
The most recent investment in OncoHost recorded on gritt.io was in May 2022.
When was OncoHost founded?
OncoHost was founded in 2017.
What industry is OncoHost in?
OncoHost operates in Hospitals and Health Care. Find similar Hospitals and Health Care investors on gritt.io.
Where is OncoHost based?
OncoHost is headquartered in Binyamina, Israel.